N-803/BCG Approval Signals Paradigm Shift in Management of BCG-Unresponsive NMIBC
Karim Chamie, MD, discusses the significance of the FDA approval of N-803 plus BCG in BCG-unresponsive non–muscle invasive bladder cancer.
Karim Chamie, MD, discusses the significance of the FDA approval of N-803 plus BCG in BCG-unresponsive non–muscle invasive bladder cancer.
In this video, Taxiarchis Kourelis, MD, Mayo Clinic, Rochester, MN, highlights key unmet needs in patients with amyloidosis, including the challenge of early diagnosis, and…
Julia Foldi, MD, PhD, discusses interstitial lung disease associated with the use of T-DXd in HER2+ breast cancer.
Most women who attempted to conceive following treatment for stage I to III breast cancer were able to become pregnant at least once.
OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.
The OncoAlert Newsletter is now out for June 23-29, 2023
OncLive® will be LIVE with OncLive® News Network: On Location at the 2024 ASCO Annual Meeting. Each day, we will broadcast a series of interviews…
Reshaping cancer clinical trials will involve embracing technology, collaboration, and innovation, explain Drs. W. Kimryn Rathmell and Shaalan Beg.
An artificial intelligence-based navigation tool may be used to call patients who previously missed their colonoscopy appointment with the goal that they will reschedule and…
Phase 1 of the Acclaim-3 study evaluating quaratusugene ozeplasmid plus atezolizumab in patients with extensive-stage small cell lung cancer has enrolled and dosed its first…
The addition of pelabresib and ruxolitinib (Jakafi) led to a significant and durable reduction in splenomegaly, among other improvements, vs ruxolitinib alone in JAK inhibitor–naive…